You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of Δ5/Δ6 desaturase. Mice injected with CP 24,879 at 3 mg/kg had a reduction of liver arachidonate content of approximately 50%. Murine mastocytoma cells treated with 5 µM CP 24,879 showed increased mead acid content and nearly complete ablation of leukotriene C4 synthesis, consistent with a desaturase inhibition-induced state of essential fatty acid deficiency.
1 Obukowicz, M.G., Raz, A., Pyla, P.D., et al. Identification and characterization of a novel Δ6/Δ5 fatty acid desaturase inhibitor as a potential anti-inflammatory agent. Biochem Pharmacol 55 1045-1058 (1998). 2 Levin, G., Duffin, K.L., Obukowicz, M.G., et al. Differential metabolism of dihomo-γ-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: Implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J 365 489-496 (2002).
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.